The DOI matches its Crossref record; 59 of the 60 references it cites were found in a registry or an index; 14 of the 26 sources its claims cite were checked for support.
Effect of Supplementation with Probiotics in Patients with Schizophrenia: Systematic Review and Meta-Analysis of Randomized Controlled Clinical Trials
Open accessAbstract
Supplementation with probiotics seems to confer protective effects in individuals with schizophrenia (SZ), although available results are inconclusive. The aim of this study was to systematically review existing randomized clinical trials (RCTs) to critically assess the effect of probiotics on psychiatric symptoms, anthropometric indicators, lipid profiles, glycemic indices, inflammation, and oxidative stress in adults with SZ. A systematic search was conducted in four databases from inception until January 2025. Six RCTs were included in the quantitative analysis that demonstrated beneficial effects of probiotics on SZ severity determined via the Positive and Negative Syndrome Scale (PANSS), with significant reductions in PANSS (MD = −0.50, p = 0.001), PANSS Negative (MD = −0.31, p = 0.050), and PANSS General scores (MD = −0.33, p = 0.036), alongside reductions in body weight (MD = −0.92, p = 0.000), body mass index (MD = −0.53, p = 0.016), and total cholesterol (SMD = −0.34, p = 0.005). Furthermore, probiotic interventions reduced baseline glucose (SMD = −0.59, p = 0.000), insulin (MD = −0.68, p = 0.000), and measures of insulin sensitivity/resistance and significantly improved biomarkers of inflammation and oxidative stress. To summarize, this meta-analysis suggests that probiotics may confer beneficial effects in patients with SZ through improving psychiatric symptoms as well as markers of body weight, lipid and glucose metabolism, inflammation, and oxidative stress.
Overview
CoChat Summary
## TL;DR
This systematic review and meta-analysis of 6 randomized controlled trials found that probiotics, often given with other supplements, were associated with improvements in several schizophrenia-related and metabolic outcomes. The pooled results showed reductions in PANSS total, PANSS Negative, PANSS General, BMI, weight, total cholesterol, glucose-related measures, hs-CRP, and oxidative stress markers, but not PANSS Positive or BPRS.
## Key findings
- Six RCTs with 361 patients with schizophrenia were included; 183 were in intervention groups and 178 in control groups.
- Psychiatric symptoms improved for some measures: total PANSS decreased (MD = −0.50, p = 0.001), PANSS Negative decreased (MD = −0.31, p = 0.050), and PANSS General decreased (MD = −0.33, p = 0.036); PANSS Positive and BPRS did not differ significantly.
- Anthropometric and lipid outcomes improved: BMI decreased (MD = −0.53, p = 0.016), weight decreased (MD = −0.92, p = 0.000), and total cholesterol decreased (SMD = −0.34, p = 0.005); TGs, LDL-C, VLDL-C, HDL-C, and total/HDL-cholesterol ratio were not significantly changed.
- Metabolic, inflammatory, and oxidative stress markers also improved: fasting glucose (SMD = −0.59, p = 0.000), HOMA-IR (MD = −0.92, p = 0.002), insulin (MD = −0.68, p = 0.000), IRI (MD = −0.67, p = 0.000), QUICKI (MD = 1.14, p = 0.000), hs-CRP (MD = −0.79, p = 0.000), GSH (MD = 0.53, p = 0.006), TAC (MD = 0.47, p = 0.014), and MDA (MD = −0.47, p = 0.014).
## Methods
- Systematic review and meta-analysis conducted according to PRISMA, registered in INPLASY (INPLASY202510113), with searches from inception to January 2025 in CENTRAL, PubMed, ScienceDirect, and Web of Science.
- Included randomized controlled trials in adults with schizophrenia that assessed at least one outcome among psychiatric symptoms, anthropometric indicators, lipid profile, glycemic indices, inflammation, or oxidative stress; 6 RCTs met criteria.
- Dual-reviewer study selection, quality assessment (RoB2 and Nutri Grade), and data extraction; pooled effect sizes were calculated in Stata v14.0 and Review Manager 5.4 using a random-effects DerSimonian–Laird model.
## Limitations
- The paper states that only six RCTs were included and that sample sizes were small.
- The paper states that co-supplementation with selenium, vitamin D, dietary fiber, or oligofructose may have confounded the effects, making it hard to isolate probiotics alone.
- The paper states that differences in baseline parameters, probiotic types, and dosages may have contributed to heterogeneity, and that long-term follow-up data were lacking because study duration was 12 weeks.
- Evident from the text: most interventions combined probiotics with other supplements, so the evidence for probiotics alone is limited.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Flow diagram of the study selection, adapted from Ref. [27].](https://figures.cochat.ai/paper-figures/d0bd555b488f4e749431493414471ce7/effect-of-supplementation-with-probiotics-in-patients-with-schizophrenia-figure-1.jpg)
![Figure 2 (top) Risk of bias summary. (bottom) Risk of bias graph [28,29,30,31,32,33].](https://figures.cochat.ai/paper-figures/f3a1cdd59763456aa80c514f98c8bdbe/effect-of-supplementation-with-probiotics-in-patients-with-schizophrenia-figure-2.jpg)
![Figure 3 The forest plot is a visual representation of the effect of probiotic consumption: (A) PANSS; (B) PANSS Negative; (C) PANSS General; (D) PANSS Positive; (E) BPRS [28,29,30,33].](https://figures.cochat.ai/paper-figures/2f25e66086ca4de094014b43e795b0b1/effect-of-supplementation-with-probiotics-in-patients-with-schizophrenia-figure-3.jpg)
![Figure 4 The forest plot is a visual representation of the effect of probiotic consumption: (A) BMI; (B) weight [31,32,33].](https://figures.cochat.ai/paper-figures/ea2a2062be1c488fba9434b32aec1c21/effect-of-supplementation-with-probiotics-in-patients-with-schizophrenia-figure-4.jpg)
![Figure 5 The forest plot is a visual representation of the effect of probiotic consumption: (A) TGs; (B) TC; (C) LDL-C; (D) VLDL-C; (E) HDL-C; (F) total/HDL-cholesterol ratio [28,29,30,31,32,33].](https://figures.cochat.ai/paper-figures/acd96d5b973f4df7aa6ab5a47f6de9b8/effect-of-supplementation-with-probiotics-in-patients-with-schizophrenia-figure-5.jpg)
![Figure 6 The forest plot is a visual representation of the effect of probiotic consumption: (A) glucose; (B) HOMA-IR; (C) insulin; (D) IRI; (E) QUICKI [28,29,30,31,32,33].](https://figures.cochat.ai/paper-figures/32de8bbb198a48a29992febc34ed571a/effect-of-supplementation-with-probiotics-in-patients-with-schizophrenia-figure-6.jpg)
![Figure 7 The forest plot is a visual representation of the effect of probiotic consumption on inflammation [28,30].](https://figures.cochat.ai/paper-figures/adc9fb8b629144679132a4f0742f9be0/effect-of-supplementation-with-probiotics-in-patients-with-schizophrenia-figure-7.jpg)
![Figure 8 The forest plot is a visual representation of the effect of probiotic consumption: (A) GSH; (B) TAC; (C) MDA [28,30].](https://figures.cochat.ai/paper-figures/115320aeaec74c1f8317fd180115121c/effect-of-supplementation-with-probiotics-in-patients-with-schizophrenia-figure-8.jpg)
Verification
Claims the paper makes
13 Valid · 1 Not valid · 9 Not checked · 41 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The gut microbiome and the brain are strongly linked, influencing brain growth and development [9,10].”
§ Effect of Supplementation with Probiotics in Patients with Schizophrenia: Systematic Review and Meta-Analysis of Randomized Controlled Clinical Trials > 1. Introduction Schizophrenia (SZ) is defined as a chronic and severe psychiatric disorder characterized by cognitive decline and physiological and emotional reduction [1]. SZ is a life-threatening disease, putting 1% of the world’s population in agony. The disease is closely related to genetic and environmental factors [2]. Accompanied by low short-term recovery rates, difficult prognoses, and poor employment rates, SZ is deeply concerning [3]. Antipsychotic medications have some ameliorative effects that can alleviate the disease symptoms, reduce relapse rates, and raise the standard of living [4]. However, the treatment of SZ with first- and second-generation antipsychotics has been reported to often be associated with side effects, including obesity and consequent increased risk of metabolic syndrome [5]. The main mechanisms underlying such trends are multifaceted, affecting several neurotransmitter systems that regulate hunger, satiety, and energy balance [6]. The affinity of various medicaments (e.g., olanzapine, quetiapine, and clozapine) to several central nervous system receptors, including serotonin, dopamine, histamine, and muscarinic receptors, is hypothesized to lead to sedation, increased appetite, higher susceptibility to cravings, and overeating [7]. Moreover, atypical antipsychotics (especially olanzapine and clozapine) may alter glucose and fat metabolism and hormonal dysfunction, with impairment of insulin sensitivity, increased leptin and ghrelin, and reduced adiponectin levels, resulting in increased fat storage and weight gain [8]. To date, there is no strong evidence of specific interventions to reduce the impact of overweight and cardiovascular disease. Hence, dietary counseling is highly warranted to guide patients toward healthy and conscious eating over the course of therapy. The gut microbiome and the brain are strongly linked, influencing brain growth and development [9,10]. Consequently, the microbiota in the gut have an important impact on mood, stress, and the nervous system through gut–brain interactions [11]. Microbial metabolites such as short chain fatty acids (SCFAs) exert beneficial effects on psychiatric disorders via the microbiota–gut–brain axis through humoral, hormonal, and immune pathways [12]. Cytokines present in the gut are important immune system mediators, through the regulation of immune cells, exerting an impact on the central system as well as on the pathogenesis of SZ [13]. Furthermore, microbial metabolites stimulate the vagus nerve, thereby exerting an important impact on brain function in SZ [14]. The homeostasis of the gut microbiota is closely related to an individual’s mood, cognition, physiological condition, and mental state, and it has a moderating effect on psychiatric disorders through the interaction of the gut–brain axis. [15]. Probiotics have a beneficial action on the gut microbiota and play an extremely important role in restoring microbial composition, altering gut microbial diversity, boosting immunity, and ameliorating disease [16]. Animal studies suggest that probiotics can modulate endogenous neuroactive molecules [17], prevent and treat neuronal autoimmune diseases [18], and ameliorate impaired spatial memory in diabetic rats [19]. Notably, the gut microbiota may confer beneficial effects on SZ by regulating the expression of neurotrophic factor receptors and the levels of inflammatory factors and chemokines, thereby alleviating metabolic dysfunction and providing a new direction for obtaining beneficial effects in patients with SZ [20,21]. Although the relationship between the gut microbiome and SZ remains unclear [22], probiotics may result in some benefits in patients with SZ in terms of both somatization symptoms and collateral effects of canon therapeutic treatment [23]. This study was designed to explore the potential therapeutic role of probiotics in patients diagnosed with SZ through regulating psychiatric symptoms, anthropometric indicators, lipid profiles, glycemic indices, inflammation, and oxidative stress.
What the sources say
- Partly supportedcites [9] Tillisch, 2014, The effects of gut microbiota on CNS function in humans, Gut Microbes sourceExperimental — accuracy not yet measured
The Introduction describes bidirectional communication between the gut microbiota and brain and says the microbiota may influence brain development. It presents that developmental influence as a possibility, supported in part by rodent studies, rather than an established effect on human brain growth and development. (LLM, conf=0.84)
- Supportedcites [10] Bauer, 2016, Microbes and the mind: Emerging hallmarks of the gut microbiota-brain axis, Cell Microbiol. source
The Introduction (page unavailable) describes bidirectional communication between gut microbes and the brain. “Critical window fluidity” (page unavailable) states that maternal microbiota impacts intrauterine brain development and that microbial exposure during early life can affect brain-related outcomes, supporting the developmental part of the paraphrase. (LLM, conf=0.90)
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“However, the use of Lactobacillus rhamnosus strain GG and Bifidobacterium animalis subsp. lactis strain Bb12 did not have an effect on PANSS scores in SZ patients in a 14-week trial [37].”
§ Effect of Supplementation with Probiotics in Patients with Schizophrenia: Systematic Review and Meta-Analysis of Randomized Controlled Clinical Trials > 4. Discussion
What the sources say
- Supportedcites [37] Dickerson, 2014, Effect of probiotic supplementation on schizophrenia symptoms and association with gastrointestinal functioning: A randomized, placebo-controlled trial, Prim. Care Companion CNS Disord. source
The Abstract identifies the two probiotic strains and the 14-week randomized trial in patients with schizophrenia. The Results report no significant difference between probiotic and placebo groups in PANSS total scores or its subscales; the Discussion summarizes this as not finding an effect on psychiatric symptoms. (LLM, conf=0.93)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Cytokines present in the gut are important immune system mediators, through the regulation of immune cells, exerting an impact on the central system as well as on the pathogenesis of SZ [13].”
§ Effect of Supplementation with Probiotics in Patients with Schizophrenia: Systematic Review and Meta-Analysis of Randomized Controlled Clinical Trials > 1. Introduction Schizophrenia (SZ) is defined as a chronic and severe psychiatric disorder characterized by cognitive decline and physiological and emotional reduction [1]. SZ is a life-threatening disease, putting 1% of the world’s population in agony. The disease is closely related to genetic and environmental factors [2]. Accompanied by low short-term recovery rates, difficult prognoses, and poor employment rates, SZ is deeply concerning [3]. Antipsychotic medications have some ameliorative effects that can alleviate the disease symptoms, reduce relapse rates, and raise the standard of living [4]. However, the treatment of SZ with first- and second-generation antipsychotics has been reported to often be associated with side effects, including obesity and consequent increased risk of metabolic syndrome [5]. The main mechanisms underlying such trends are multifaceted, affecting several neurotransmitter systems that regulate hunger, satiety, and energy balance [6]. The affinity of various medicaments (e.g., olanzapine, quetiapine, and clozapine) to several central nervous system receptors, including serotonin, dopamine, histamine, and muscarinic receptors, is hypothesized to lead to sedation, increased appetite, higher susceptibility to cravings, and overeating [7]. Moreover, atypical antipsychotics (especially olanzapine and clozapine) may alter glucose and fat metabolism and hormonal dysfunction, with impairment of insulin sensitivity, increased leptin and ghrelin, and reduced adiponectin levels, resulting in increased fat storage and weight gain [8]. To date, there is no strong evidence of specific interventions to reduce the impact of overweight and cardiovascular disease. Hence, dietary counseling is highly warranted to guide patients toward healthy and conscious eating over the course of therapy. The gut microbiome and the brain are strongly linked, influencing brain growth and development [9,10]. Consequently, the microbiota in the gut have an important impact on mood, stress, and the nervous system through gut–brain interactions [11]. Microbial metabolites such as short chain fatty acids (SCFAs) exert beneficial effects on psychiatric disorders via the microbiota–gut–brain axis through humoral, hormonal, and immune pathways [12]. Cytokines present in the gut are important immune system mediators, through the regulation of immune cells, exerting an impact on the central system as well as on the pathogenesis of SZ [13]. Furthermore, microbial metabolites stimulate the vagus nerve, thereby exerting an important impact on brain function in SZ [14]. The homeostasis of the gut microbiota is closely related to an individual’s mood, cognition, physiological condition, and mental state, and it has a moderating effect on psychiatric disorders through the interaction of the gut–brain axis. [15]. Probiotics have a beneficial action on the gut microbiota and play an extremely important role in restoring microbial composition, altering gut microbial diversity, boosting immunity, and ameliorating disease [16]. Animal studies suggest that probiotics can modulate endogenous neuroactive molecules [17], prevent and treat neuronal autoimmune diseases [18], and ameliorate impaired spatial memory in diabetic rats [19]. Notably, the gut microbiota may confer beneficial effects on SZ by regulating the expression of neurotrophic factor receptors and the levels of inflammatory factors and chemokines, thereby alleviating metabolic dysfunction and providing a new direction for obtaining beneficial effects in patients with SZ [20,21]. Although the relationship between the gut microbiome and SZ remains unclear [22], probiotics may result in some benefits in patients with SZ in terms of both somatization symptoms and collateral effects of canon therapeutic treatment [23]. This study was designed to explore the potential therapeutic role of probiotics in patients diagnosed with SZ through regulating psychiatric symptoms, anthropometric indicators, lipid profiles, glycemic indices, inflammation, and oxidative stress.
What the sources say
- Partly supportedcites [13] Dawidowski, B., Górniak, A., Podwalski, P., Lebiecka, Z., Misiak, B., and Samochowiec, J. (2021). The Role of Cytokines in the Pathogenesis of Schizophrenia. J. Clin. Med., 10. sourceExperimental — accuracy not yet measured
The Introduction says cytokines regulate immune-cell activity and may affect neurodevelopment and behavior; the Conclusions link cytokines to schizophrenia pathogenesis. The Introduction and section 6 discuss a possible link between gut microbiome disturbance and peripheral or cerebrospinal-fluid cytokines, but do not establish that the cytokines described are present in the gut or that gut cytokines exert the stated effects. (LLM, conf=0.84)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“MCIDs ranged from 14.02 to 31.50 for PANSS [34].”
§ Effect of Supplementation with Probiotics in Patients with Schizophrenia: Systematic Review and Meta-Analysis of Randomized Controlled Clinical Trials > 4. Discussion
What the sources say
- Supportedcites [34] Si, T., Shi, C., Sun, L., Zhang, Y., and Zhang, L. (2021). Assessment of the Minimum Clinically Important Difference in Symptoms and Functions of Patients with Acute Schizophrenia: A Post hoc Analysis of an Open-Label, Single-Arm Multicenter Study. Front. Psychiatry, 12. source
The Results section (“MCID Threshold Values for the Outcome Measurements”) states that PANSS MCID thresholds varied from 14.02 to 31.50 across calculation methods. These estimates came from patients with acutely exacerbated schizophrenia. (LLM, conf=0.95)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Furthermore, microbial metabolites stimulate the vagus nerve, thereby exerting an important impact on brain function in SZ [14].”
§ Effect of Supplementation with Probiotics in Patients with Schizophrenia: Systematic Review and Meta-Analysis of Randomized Controlled Clinical Trials > 1. Introduction Schizophrenia (SZ) is defined as a chronic and severe psychiatric disorder characterized by cognitive decline and physiological and emotional reduction [1]. SZ is a life-threatening disease, putting 1% of the world’s population in agony. The disease is closely related to genetic and environmental factors [2]. Accompanied by low short-term recovery rates, difficult prognoses, and poor employment rates, SZ is deeply concerning [3]. Antipsychotic medications have some ameliorative effects that can alleviate the disease symptoms, reduce relapse rates, and raise the standard of living [4]. However, the treatment of SZ with first- and second-generation antipsychotics has been reported to often be associated with side effects, including obesity and consequent increased risk of metabolic syndrome [5]. The main mechanisms underlying such trends are multifaceted, affecting several neurotransmitter systems that regulate hunger, satiety, and energy balance [6]. The affinity of various medicaments (e.g., olanzapine, quetiapine, and clozapine) to several central nervous system receptors, including serotonin, dopamine, histamine, and muscarinic receptors, is hypothesized to lead to sedation, increased appetite, higher susceptibility to cravings, and overeating [7]. Moreover, atypical antipsychotics (especially olanzapine and clozapine) may alter glucose and fat metabolism and hormonal dysfunction, with impairment of insulin sensitivity, increased leptin and ghrelin, and reduced adiponectin levels, resulting in increased fat storage and weight gain [8]. To date, there is no strong evidence of specific interventions to reduce the impact of overweight and cardiovascular disease. Hence, dietary counseling is highly warranted to guide patients toward healthy and conscious eating over the course of therapy. The gut microbiome and the brain are strongly linked, influencing brain growth and development [9,10]. Consequently, the microbiota in the gut have an important impact on mood, stress, and the nervous system through gut–brain interactions [11]. Microbial metabolites such as short chain fatty acids (SCFAs) exert beneficial effects on psychiatric disorders via the microbiota–gut–brain axis through humoral, hormonal, and immune pathways [12]. Cytokines present in the gut are important immune system mediators, through the regulation of immune cells, exerting an impact on the central system as well as on the pathogenesis of SZ [13]. Furthermore, microbial metabolites stimulate the vagus nerve, thereby exerting an important impact on brain function in SZ [14]. The homeostasis of the gut microbiota is closely related to an individual’s mood, cognition, physiological condition, and mental state, and it has a moderating effect on psychiatric disorders through the interaction of the gut–brain axis. [15]. Probiotics have a beneficial action on the gut microbiota and play an extremely important role in restoring microbial composition, altering gut microbial diversity, boosting immunity, and ameliorating disease [16]. Animal studies suggest that probiotics can modulate endogenous neuroactive molecules [17], prevent and treat neuronal autoimmune diseases [18], and ameliorate impaired spatial memory in diabetic rats [19]. Notably, the gut microbiota may confer beneficial effects on SZ by regulating the expression of neurotrophic factor receptors and the levels of inflammatory factors and chemokines, thereby alleviating metabolic dysfunction and providing a new direction for obtaining beneficial effects in patients with SZ [20,21]. Although the relationship between the gut microbiome and SZ remains unclear [22], probiotics may result in some benefits in patients with SZ in terms of both somatization symptoms and collateral effects of canon therapeutic treatment [23]. This study was designed to explore the potential therapeutic role of probiotics in patients diagnosed with SZ through regulating psychiatric symptoms, anthropometric indicators, lipid profiles, glycemic indices, inflammation, and oxidative stress.
What the sources say
- Partly supportedcites [14] Han, 2022, Vagus Nerve and Underlying Impact on the Gut Microbiota-Brain Axis in Behavior and Neurodegenerative Diseases, J. Inflamm. Res. sourceExperimental — accuracy not yet measured
The section “How Does Vagus Nerve Pick Up Multiple Signals from the Gut Microbiota?” describes the microbial metabolite butyrate stimulating vagal afferent terminals. The “Gut Microbiota–Brain Axis is a Complicated Network” section describes vagal communication with the brain, but the paper does not establish this mechanism or its impact on brain function specifically in schizophrenia. No page numbers were available in our copy. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
37 more claims · 1 with their cited sources checked
Create a free account to see all 64 claims and every source verdict.
- Probably not a substantial claim. 13
- It may state two separate claims as one. 12
Citations
Cites
The PRISMA 2020 statement: An updated guideline for reporting systematic reviews
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., et al. (2021) · BMJ · doi:10.1136/bmj.n71 · Cited by 108,283
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139 · cited 1×
“[26].”
RoB 2: a revised tool for assessing risk of bias in randomised trials
Sterne, J. A. C., Savović, J., Page, M. J., Elbers, R. G., Blencowe, N. S., Boutron, I., Cates, C. J., Cheng, H.-Y., Corbett, M. S., Eldridge, S. M., et al. (2019) · BMJ · doi:10.1136/bmj.l4898 · Cited by 34,787 · cited 1×
“Study quality was evaluated across five domains: randomization, intervention deviations, missing data, outcome measurement, and selective reporting [24].”
Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour
Cryan, J. F., & Dinan, T. G. (2012) · Nature Reviews Neuroscience · doi:10.1038/nrn3346 · Cited by 4,572 · cited 1×
“[15].”
The role of short-chain fatty acids in microbiota–gut–brain communication
Dalile, B., Van Oudenhove, L., Vervliet, B., & Verbeke, K. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0157-3 · Cited by 3,357 · cited 1×
“Microbial metabolites such as short chain fatty acids (SCFAs) exert beneficial effects on psychiatric disorders via the microbiota–gut–brain axis through humoral, hormonal, and immune pathways [12].”
Insel, T. R. (2010) · Nature · doi:10.1038/nature09552 · Cited by 1,783 · cited 1×
“Accompanied by low short-term recovery rates, difficult prognoses, and poor employment rates, SZ is deeply concerning [3].”
Gut/brain axis and the microbiota
Mayer, E. A., Tillisch, K., & Gupta, A. (2015) · Journal of Clinical Investigation · doi:10.1172/jci76304 · Cited by 1,503 · cited 1×
“Consequently, the microbiota in the gut have an important impact on mood, stress, and the nervous system through gut–brain interactions [11].”
Metabolic and cardiovascular adverse effects associated with antipsychotic drugs.
De Hert, M., Detraux, J., van Winkel, R., Yu, W., & Correll, C. U. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.156 · Cited by 1,145 · cited 1×
“However, the treat-ment of SZ with first-and second-generation antipsychotics has been reported to often be associated with side effects, including obesity and consequent increased risk of metabolic syndrome [5].”
Definition and description of schizophrenia in the DSM-5
Tandon, R., Gaebel, W., Barch, D. M., Bustillo, J., Gur, R. E., Heckers, S., Malaspina, D., Owen, M. J., Schultz, S., Tsuang, M., et al. (2013) · Schizophrenia Research · doi:10.1016/j.schres.2013.05.028 · Cited by 807 · cited 1×
“Schizophrenia (SZ) is defined as a chronic and severe psychiatric disorder characterized by cognitive decline and physiological and emotional reduction [1].”
Inflammation in schizophrenia: pathogenetic aspects and therapeutic considerations.
Müller, N. (2018) · Schizophrenia Bulletin · doi:10.1093/schbul/sby024 · Cited by 648 · cited 1×
“Low-level inflammation exacerbates the symptoms of SZ through dopaminergic, serotonergic, noradrenergic, and glutamatergic neurotransmission [51].”
Cited by
Shu, D., Zhang, T., Dong, Y., Xu, J., & Yuan, Y. (2026) · Food Chemistry X · doi:10.1016/j.fochx.2026.103802 · Cited by 14
“…Weiskirchen, & Weiskirchen, 2024; Zhang et al., 2024), reducing cancer-related risk (Chen et al., 2024); the regulation of nerves (Lan et al., 2023; Li et al., 2025; Sun et al., 2025), and the reduction of blood sugar and lipids (Jing et al., 2025; Wang, Wu, Dhital, Yu, & Chen, 2025; Zhu et al.,…”
Lakshmi, B. A., Buddolla, V., Gubbiyappa, K. S., Suneetha, M., & Kim, Y. J. (2026) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2026.111636 · Cited by 4
Škutová, K., Fišar, Z., & Hroudová, J. (2026) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2026.111749 · Cited by 2
Gut dysbiosis: An overlooked pharmacokinetic modifier in psychotropic therapy
Alaili, M. K. A. (2026) · Precision medication. · doi:10.1016/j.prmedi.2026.100098
Probiotics in reducing negative symptoms of schizophrenia: A systematic review and meta-analysis
Ramirez, J., Maresca, T., Lopez, P., Corral, R., Corrales, A., Cabrera, A., Romero‐Ferreiro, V., & Solmi, M. (2026) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2026.111820
Metadata
- Authors
- Li, L., Du, F., Liu, X., Song, M., Grosso, G., Battino, M., Boesch, C., Li, H., & Liu, X.
- Affiliations
- Beijing Technology and Business University (CN)
- University of Catania (IT)
- Jiangsu University (CN)
- University of Leeds (GB)
- Corresponding author
- Li, Lu
- Liu, Xinqi
- ORCID
- Venue
- Foods
- Publisher
- MDPI AG
- Published
- 2025-05-16
- Volume
- 14
- Issue
- 10
- Pages
- 1773
- ISSN
- 2304-8158 (ISSN-L)
- PMC
- PMC12111037
- OpenAlex
- W4410439031
- Cited by
- 8
- References
- 60
- Citations by year
- 2026: 8
- FWCI
- 0.54
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Foods (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (acceptedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Università Politecnica delle Marche (Università Politecnica delle Marche) (submittedVersion, cc-by)
- Topics
- Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Keywords
- probiotics, schizophrenia, psychiatric symptoms, body weight, body mass index, lipid profile, cholesterol, glycemic control, insulin sensitivity, insulin resistance, inflammation, oxidative stress, gut microbiota
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effect of Supplementation with Probiotics in Patients with Schizophrenia: Systematic Review and Meta-Analysis of Randomized Controlled Clinical Trials. https://app.cochat.ai/papers/10.3390/foods14101773
- The paper
- Li, L., Du, F., Liu, X., Song, M., Grosso, G., Battino, M., Boesch, C., Li, H., & Liu, X. (2025). Effect of Supplementation with Probiotics in Patients with Schizophrenia: Systematic Review and Meta-Analysis of Randomized Controlled Clinical Trials. Foods. https://doi.org/10.3390/foods14101773
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.